Hypericin-mediated photodynamic therapy induces apoptosis in K562 human leukemia cells through JNK pathway modulation

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6475-6482

  Xu, Yixiao ^a,b   Wang, Dexuan ^c   Zhuang, Zhizhi ^c   Jin, Keke ^b   Zheng, Lvzhen ^b   Yang, Qing ^c   Guo, Kunyuan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; C Jun N terminal kinase; Hypericin; K562; Photodynamic therapy

Indexed keywords

CASPASE; HYPERICIN; STRESS ACTIVATED PROTEIN KINASE 1; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PERYLENE; PHOTOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REGULATION; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA; LIGHT INTENSITY; MICROSCOPY; MITOCHONDRION; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; K-562 CELL LINE; LIGHT; METABOLISM; PHOTOCHEMOTHERAPY; PROCEDURES; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LIGHT; MAP KINASE KINASE 4; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84943638822     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4258     Document Type: Article

References (33)

1. Panzarini E, Inguscio V, Fimia GM and Dini L: Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells. PLoS One 9: e105778, 2014.
2. Martirosyan AS, Vardapetyan HR, Tiratsuyan SG and Hovhannisyan AA: Biphasic dose-response of antioxidants in hypericin-induced photohemolysis. Photodiagnosis Photodyn Ther 8: 282-287, 2011.
3. Plaetzer K, Krammer B, Berlanda J, Berr F and Kiesslich T: Photophysics and photochemistry of photodynamic therapy: Fundamental aspects. Lasers Med Sci 24: 259-268, 2009.
4. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin 61: 250-281, 2011.
5. Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS and Choi YD: Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancerrefractory or intolerant to bacille Calmette-Guérin immunotherapy. J Urol 190: 1192-1199, 2013.
6. Gray J and Fullarton GM: Long term efficacy of photodynamic therapy (PDT) as an ablative therapy of high grade dysplasia in Barrett's oesophagus. Photodiagnosis Photodyn Ther 10: 561-565, 2013.
7. Lo VC, Akens MK, Wise-Milestone L, Yee AJ, Wilson BC and Whyne CM: The benefits of photodynamic therapy on vertebral bone are maintained and enhanced by combination treatment with bisphosphonates and radiation therapy. J Orthop Res 31: 1398-1405, 2013.
8. Krammer B and Verwanger T: Molecular response to hypericin-induced photodamage. Curr Med Chem 19: 793-798, 2012.
9. Nakajima N and Kawashima N: A basic study on hypericin-PDT in vitro. Photodiagnosis Photodyn Ther 9: 196-203, 2012.
10. Lima AM, Pizzol CD, Monteiro FB, Creczynski-Pasa TB, Andrade GP, Ribeiro AO and Perussi JR: Hypericin encapsulated in solid lipid nanoparticles: Phototoxicity and photodynamic efficiency. J Photochem Photobiol B 125: 146-154, 2013.
11. Ehrenberg B, Anderson JL and Foote CS: Kinetics and yield of singlet oxygen photosensitized by hypericin in organic and biological media. Photochem Photobiol 68: 135-140, 1998.
12. Kleemann B, Loos B, Scriba TJ, Lang D and Davids LM: St John's Wort (Hypericum perforatum L.) photomedicine: Hypericin-photodynamic therapy induces metastatic melanoma cell death. PLoS One 9: e103762, 2014.
13. Zheng Y, Le V, Cheng Z, Xie S, Li H, Tian J and Liu J: Development of rapid and highly sensitive HSPA1A promoter-driven luciferase reporter system for assessing oxidative stress associated with low-dose photodynamic therapy. Cell Stress Chaperones 18: 203-213, 2013.
14. Tan B, Anaka M, Deb S, Freyer C, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, Chen W and Mariadason JM: FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget 15: 264-276, 2014.
15. Miccoli L, Beurdeley-Thomas A, De Pinieux G, Sureau F, Oudard S, Dutrillaux B and Poupon MF: Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res 58: 5777-5786, 1998.
16. Chen B, Roskams T, Xu Y, Agostinis P and de Witte PA: Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer 98: 284-290, 2002.
17. Roelants M, Van Cleynenbreugel B, Lerut E, Van Poppel H and de Witte PA: Human serum albumin as key mediator of the differential accumulation of hypericin in normal urothelial cell spheroids versus urothelial cell carcinoma spheroids. Photochem Photobiol Sci 10: 151-159, 2011.
18. Kim HB, Kim MJ, Lee SH, Lee JW, Bae JH, Kim DW, Dao TT, Oh WK, Kang CD and Kim SH: Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis. Biochem Pharmacol 84: 402-410, 2012.
19. Fox FE, Niu Z, Tobia A and Rook AH: Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed and malignant T lymphocytes: Implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol 111: 327-332, 1998.
20. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A and Cabana B: A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol 63: 984-990, 2010.
21. Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B and Plaetzer K: Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 25: 173-188, 2006.
22. Buytaert E, Callewaert G, Hendrickx N, Scorrano L, Hartmann D, Missiaen L, Vandenheede JR, Heirman I, Grooten J and Agostinis P: Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J 20: 756-758, 2006.
23. Sanovic R, Krammer B, Grumboeck S and Verwanger T: Time-resolved gene expression profiling of human squamous cell carcinoma cells during the apoptosis process induced by photodynamic treatment with hypericin. Int J Oncol 35: 921-939, 2009.
24. Ali SM, Chee SK, Yuen GY and Olivo M: Hypocrellins and Hypericin induced apoptosis in human tumor cells: A possible role of hydrogen peroxide. Int J Mol Med 9: 461-472, 2002.
25. Koval J, Mikes J, Jendzelovski R, Kello M, Solár P and Fedorocko P: Degradation of HER2 receptor through hypericin-mediated photodynamic therapy. Photochem Photobiol 86: 200-205, 2010.
26. Skulachev VP: The programmed death phenomena, aging and the Samurai law of biology. Exp Gerontol 36: 995-1024, 2001.
27. Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene 27: 6245-6251, 2008.
28. Varfolomeev EE and Ashkenazi A: Tumor necrosis factor: An apoptosis JuNKie?. Cell 116: 491-497, 2004.
29. Feng Q, Cao HL, Xu W, Li XR, Ren YQ and Du LF: Apoptosis induced by genipin in human leukemia K562 cells: Involvement of c-Jun N-terminal kinase in G2/M arrest. Acta Pharmacol Sin 32: 519-527, 2011.
30. Chen YJ, Liu WH, Kao PH, Wang JJ and Chang LS: Involvement of p38 MAPK-and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon 55: 1306-1316, 2010.
31. Takamura M, Matsuda Y, Yamagiwa S, Tamura Y, Honda Y, Suzuki K, Ichida T and Aoyagi Y: An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins. Life Sci 80: 1335-1344, 2007.
32. Lee S, Park HS, Notsu Y, Ban HS, Kim YP, Ishihara K, Hirasawa N, Jung SH, Lee YS, Lim SS, et al: Effects of hyperin, isoquercitrin and quercetin on lipopolysaccharide-induced nitrite production in rat peritoneal macrophages. Phytother Res 22: 1552-1556, 2008.
33. Zhang Z, Sethiel MS, Shen W, Liao S and Zou Y: Hyperoside downregulates the receptor for advanced glycation end products (RAGE) and promotes proliferation in ECV304 cells via the c-Jun N-terminal kinases (JNK) pathway following stimulation by advanced glycation end-products in vitro. Int J Mol Sci 14: 22697-22707, 2013.